FDA Crisis as Director Resigns to Join Philip Morris

Aug.11.2022
FDA Crisis as Director Resigns to Join Philip Morris
US FDA official resigns to join tobacco company amid e-cigarette regulation delays and controversy.

Matthew Holman, Director of the Science Office at the Center for Tobacco Products (CTP) of the US Food and Drug Administration (FDA), is reportedly resigning in July to join Philip Morris International. His departure comes amid a crisis for the CTP, which has postponed decisions on the fate of hundreds of thousands of electronic cigarette products.


In September 2020, e-cigarette manufacturers were required to submit a Pre-Market Tobacco Product Application (PMTA) in order to continue offering their products for retail. In September of the following year, the FDA issued a ban on nearly one million flavored e-cigarette and e-liquid products, prompting many small-scale manufacturers, including all those active in the market since 2016, to switch from tobacco-derived nicotine to synthetic nicotine.


Lawmakers, who seem to act swiftly only on issues related to electronic cigarettes, have proposed and passed legislation allowing the FDA to regulate synthetic nicotine as a tobacco product. As a result, manufacturers of e-cigarette oils and other products must submit a new Pre-Market Tobacco Application (PMTA) by May 14, 2022 in order to sell their newly classified tobacco products.


Throughout the entire process, the FDA has faced pressure from members of Congress, so-called public health groups, and anti-vaping movements, to exert their administrative power and establish numerous standards, including prohibiting the use of flavorings and any level of nicotine content.


Throughout the PMTA process, one thing is certain: the agency overlooked the science. Now, it appears that the science has had enough and is stepping out to support a tobacco company that is more committed to reducing adult smoking rates than the FDA.


E-cigarettes and vaping devices are not the only products available for adult consumers looking to reduce tobacco harm. Smokeless tobacco, snus, and heated tobacco products offer alternatives that allow consumers to enjoy the benefits of nicotine without the harmful effects associated with tobacco combustion.


Although the FDA has been slow in approving pending applications, they have acknowledged that tobacco products carry continuous risks, with combustible cigarettes being the most harmful and nicotine replacement therapies posing the least amount of harm. After obtaining marketing authorization through PMTA (or other regulatory pathways), manufacturers can apply to modify modified risk tobacco product (MRTP) orders. So far, the FDA has only granted 14 MRTP orders.


Phimo International's heated tobacco product, IQOS, has obtained marketing and MRTP orders through the PMTA process. Unfortunately, due to patent disputes, US adult tobacco consumers are unable to purchase FDA-approved IQOS. However, Phimo International's new reduced-risk tobacco product is causing a rapid decline in smoking rates in other parts of the world.


In Japan, since 2016, heated tobacco products including IQOS have helped reduce cigarette sales by 42%. Furthermore, researchers from the American Cancer Society report that "the introduction of IQOS may reduce cigarette sales in Japan.


Although the FDA may recognize the potential of products such as IQOS to reduce tobacco harm, the agency still refuses to consider data on flavor use and enjoyment in electronic cigarette products among adults. Flavorings help adults quit smoking and maintain a non-smoking status.


The popularity of flavored e-cigarettes among adult users has been on the rise following the FDA's rejection of nearly one million flavored vaping products. Several surveys and studies have confirmed this trend.


For example, a survey conducted in 2018 of nearly 70,000 adult e-cigarette users in the United States found that "flavor plays a critical role in the use of e-cigarettes and e-cigarette devices", with 83.2% and 72.3% of respondents respectively indicating that they used fruit and dessert flavors. Additionally, a study in 2020 found a correlation between flavor and smoking cessation. In a cohort study of more than 17,900 participants, the authors found that "adults who started using non-tobacco-flavored e-cigarettes were more likely to quit smoking than those who used tobacco-flavored e-cigarettes.


Unfortunately, these studies do not appear to have swayed the FDA, which seems to have given in to the whims of lawmakers rather than examining the data, science, and absolute number of products to determine safer alternatives for adults.


Hallman left a company claiming to reduce smoking and joined PhiMo International, which highlights a potential theme: tobacco and e-cigarette companies are more committed to helping adults quit smoking than the FDA.


Statement


This article is compiled from third-party information and is intended only for industry exchange and learning.


This article does not represent the viewpoint of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of its contents. The compilation of this article is solely for industry exchange and research purposes.


Due to limitations in the quality of our translation, the compiled article may not express the original text accurately. Please refer to the original text for accuracy.


2FIRSTS agrees with the Chinese government on all domestic, Hong Kong, Macao, Taiwan, and foreign-related remarks and positions.


The rights to compile information belong to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
Hawaii's Largest Independent Vape Retailer and Wholesaler Volcano to Close All 13 Stores Ahead of 2027 Sales Rules
Hawaii's Largest Independent Vape Retailer and Wholesaler Volcano to Close All 13 Stores Ahead of 2027 Sales Rules
Hawaii-based vaping company Volcano eCigs plans to close all 13 physical retail stores on December 31, 2026, affecting approximately 56 employees. Volcano operates retail, wholesale, proprietary product and online sales businesses and has previously described itself in legislative testimony as Hawaii's largest independent vape retailer and wholesaler. Its operating company, Jocor Enterprises LLC, filed a formal closure notice on November 4, citing changes in the state's regulatory environment. From January 1, 2027, Hawaii will restrict the sale, acquisition and possession of vaping devices and e-liquids not listed in a state product directory, alongside separate restrictions on certain disposable devices. The closure concerns Volcano's physical retail network; the company has not announced the termination of wholesale or online operations.
Market
Nov.09
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
AIR Global PLC (NASDAQ: AIIR) announced on November 5, 2026, that it had submitted a Premarket Tobacco Product Application (PMTA) to the U.S. Food and Drug Administration (FDA) for Crown Switch, its rechargeable pod vape platform. First launched in Germany in November 2025, the device uses Quantum Chip atomization technology developed by Canadian vaporization technology company Greentank Innovations. German retail versions feature 2mL prefilled pods containing 18mg/mL nicotine in six flavors, while AIR has separately tested two 5% nicotine formulations intended for U.S. development. AIR invested $20 million in Greentank in July and reported approximately $3.4 million in U.S. PMTA-related regulatory costs for the first nine months of 2026. The Crown Switch application has been submitted, but the FDA has not granted marketing authorization.
product
Nov.13
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25